H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 3,767 million. An increase of 7% compared to the second quarter results of 2009. Profit from operations was DKK 936 million, an increase of 30% compared to the same period last year.
Original Source of Lundbeck reports strongly increasing profits…
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what’s happening to them can be a challenge.
Original Source of Abbott Launches New Psoriasisanswers.com Web site
The European Medicines Agency (EMA) and the Food and Drug Administration of the United States of America (US FDA) continue to seek potential candidate companies for a joint GMP inspection pilot programme for manufacturers of medicinal products.
Original Source of EMA and US FDA seek potential candidate companies for joint…
30 September 2010, Frankfurt, Germany. Pharma Marketing 2010 in Frankfurt provides a key platform for Europe’s pharmaceutical industry stakeholders, such as yourself, to discover how best to tackle the key challenges of a price-sensitive and increasingly competitive and rapidly changing market.
Original Source of Pharma Marketing 2010 – Frankfurt
Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix(R) (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.
Original Source of Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial
Pfizer Inc. (NYSE: PFE) has reported financial results for second-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first two quarters of 2010, but not reflected in the first two quarters of 2009.
Original Source of Pfizer…
An international team of scientists has identified 95 genetic variants associated with high blood cholesterol and triglyceride levels which are major risk factors for coronary heart disease. The study, published in the journal Nature and funded in part by the EU, could lead to novel ways of preventing and treating…
Detailed pictures showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments.(1) The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections.
Original Source of Image of new antibiotic in action opens up…
29 – 30 September 2010, Frankfurt, Germany. In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments.
Original Source of Clinical Trials 2010 – Frankfurt…
H. Lundbeck A/S (Lundbeck) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension.
Original Source of TEMPO study further demonstrates the benefits of Azilect® in early Parkinson’s disease patients